Loading stock…

Ligand Pharmaceuticals Incorporated (LGND) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Ligand Pharmaceuticals Incorporated

LGNDMarket cap $5.85BPrice $293.3

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Licenses a portfolio of royalty-generating drug technologies to biotech and pharma partners instead of manufacturing medicines itself. Collects royalties on dozens of approved products, turning other companies' R&D risk into its own steady, high-margin income stream.

In Bastion Portfolios?

52W Return+61%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+18%9

Rev CAGR (5y)+19%9

Earnings Forecast

EPS Growth Y+1+55%9

EPS Growth Y+2+35%9

EPS Growth Y+3+26%8

Quality

Margins

EBIT Margin34%9

Net Income Margin68%10

Free Cash Flow Margin45%10

Debt

Net Debt/EBITDA-1.710

Efficiency

ROE22%8

ROA13%9

Earnings Stability44

GEAR+VERY STRONG89

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)263

P/E Ratio (Forward 3y)174

P/BV6.03

EV Multiples

EV/EBITDA Fwd282

EV/EBIT Fwd451

Yield

Free Cash Flow Yield2.2%4

Dividend Yieldna–

Momentum

Short term

1 month return+2%8

3 month return-7%4

YTD return+55%9

Mid term

Price vs 52wHigh90%8

1 year return+59%9

Long term

3 year return+404%10

5 year return+256%9

Risk Shield

Price Risk

Beta0.94

Volatility37%5

Free Cash Flow

Free Cash Flow Margin45%10

Free Cash Flow Yield2.2%4

Quality

ROCE7%4

Earnings Stability44

Net Debt/EBITDA-1.710

02Growth

Is it actually growing, and how fast?

LGNDLigand Pharmaceuticals

Revenue FY25$268M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+19%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+55%9

EPS growth, FY27E+35%9

EPS growth, FY28E+26%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 11%/yr over the last 3 years and is set to grow 18%/yr from here.

The runway holds up: revenue is set to grow 19%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 35%/yr vs revenue 18%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-7%4

YTD return+55%9

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+59%9

3-year return+404%10

5-year return+256%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +404% over three years and +256% over five, ahead of 90% of the market.

It's up 59% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and so far this year (+55%).

WATCH

Returns sit at the market level over three months (-7%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Ligand Pharmaceuticals Incorporated. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

LGNDLigand Pharmaceuticals

Revenue FY25$268M

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+19%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+55%9

EPS growth, FY27E+35%9

EPS growth, FY28E+26%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 11%/yr over the last 3 years and is set to grow 18%/yr from here.

The runway holds up: revenue is set to grow 19%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 35%/yr vs revenue 18%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG85 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-7%4

YTD return+55%9

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+59%9

3-year return+404%10

5-year return+256%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +404% over three years and +256% over five, ahead of 90% of the market.

It's up 59% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+2%) and so far this year (+55%).

WATCH

Returns sit at the market level over three months (-7%).

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Ligand Pharmaceuticals Incorporated. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community